MedTrace Logo

Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)

NCT00480077 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 335

Last updated 2025-07-02

Study results available
· View outcomes & findings →

Summary

The DOT-HF trial is an international, prospective, multi-center, randomized, controlled trial.

Conditions

Interventions

DEVICE

Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )

OptiVol® Fluid status Monitoring with Cardiac Compass

Sponsors & Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • Prof. D.J. van Veldhuisen, MD · Groningen University Hospital, The Netherlands

  • Prof. Dr. med. M. Borggrefe · Ruprecht-Karls-Universität Heidelberg, Germany

  • Prof. Dr. V. Conraads · Universitair Ziekenhuis Brussel

  • Prof. C.M. Yu · Prince of Wales Hospital, Shatin, Hong Kong

  • Dr. F. Braunschweig · Karolinska University Hospital

  • Prof. Dr. J. Kautzner · IKEM- Klinika Kardiologie, Czech Republic

  • Prof. Dr. G. Jondeau · Hôpital Bichat Claude Bernard, France

  • Prof. Dr. M.R. Cowie · National Heart & Lung Institute, United Kingdom

  • Dr. R. Muñoz-Aguilera · Hospital General Universitario Gregorio Marañon, Spain

  • Prof. I. Ford · Robertson Center for Biostatistics, Scotland

  • Dr. M Lunati · Azienda Ospedaliera Niguarda Ca' Granda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00480077 on ClinicalTrials.gov